ArticleFrontiers in oncology2022

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation.

Shibin Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.